Pill Burden: A Major Barrier to HAART Adherence and Fixed Dose Combinations (FDCS) as its Solution – A Mini-Review
- 1 May 2024
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 22 (3) , 143-152
Abstract
: HIV/ AIDS is a global pandemic, one of the most challenging; with no cure for the disease, various therapies available in the form of regimens as Highly Active Anti-Retroviral Therapy (HAART) or simply Anti-Retroviral Therapy (ART) are the only way to manage the disease. The Fixed Dose Combinations (FDCs) concept has been a well-recognised improvement in pharmacotherapy for the treatment of a variety of chronic maladies like hypertension, diabetes, HIV/AIDS, and several FDC products consisting of HIV drugs are approved. These single-tablet regimens have been essential in streamlining ART, lowering pill burden and increasing adherence. Adherence to HAART is the most vital factor to ensure medication success and virologic suppression. However, adherence is faced with several barriers including adverse effects of drugs, the complexity of ART, social-cultural factors, and pill burden among others. This writing reviews the concept of adherence to ART, and its barriers while stressing pill burden as a significant one which we suggest would be solved by using Fixed Dose Combinations (FDCs).Keywords
This publication has 72 references indexed in Scilit:
- Antiretroviral Drugs for Treatment and Prevention of HIV Infection in AdultsJAMA, 2023
- Real-World Adherence to Antiretroviral Therapy Among HIV-1 Patients Across the United StatesAdvances in Therapy, 2021
- HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and SafetyDrugs, 2020
- Pharmacokinetic Parameters of HIV‐1 Protease InhibitorsChemMedChem, 2020
- Review of Drugs Approved via the 505(b)(2) Pathway: Uncovering Drug Development Trends and Regulatory RequirementsTherapeutic Innovation & Regulatory Science, 2020
- Evaluation of human immunodeficiency virus medication errors in a community hospital following the implementation of a pharmacist‐led antiretroviral stewardship programJACCP: Journal of the American College of Clinical Pharmacy, 2019
- Doravirine: First Global ApprovalDrugs, 2018
- Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral TherapyPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016
- Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individualsCochrane Database of Systematic Reviews, 2010
- Comparison of various measures for assessing medication refill adherence using prescription dataPharmacoepidemiology and Drug Safety, 2008